Skip to search formSkip to main contentSkip to account menu

Noxafil

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Les medicaments sont indispensables pour la sante mais leur usage n’est pas anodin. Les indications autorisees du dossier d’AMM d… 
2016
2016
Solid-state NMR (ssNMR) spectroscopy has shown its indispensable capability of elucidating atomic level structures and… 
2015
2015
Objectives: Compare the cost of the primary prophylaxis of invasive fungal infections (IFI) with voriconazole, posaconazole, and… 
Review
2008
Review
2008
The incidence of fungal infections has dramatically increased in the past few decades.1,2 These infections contribute… 
2006
2006
Noxafil oral suspension, a new antifungal agent from Schering-Plough Corp., received marketing approval for the prevention of… 
2003
2003
Posaconazole [SCH 56592, SPRIAFIL, Noxafil] is an orally active triazole derivative that is in phase III trials with the Schering…